What's Going On With Molecular Templates Stock?

Molecular Templates, Inc MTEM shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. 

The Details:

Molecular Templates said the findings show that MT-6402 acts uniquely from other approved checkpoint agents and was well-tolerated with no drug-related Grade 4 or Grade 5 adverse events observed.

“We are excited to see objective responses in heavily pre-treated, checkpoint-experienced, head and neck cancer patients, a setting with high unmet medical need,” said CEO Eric Poma. 

“The long-lasting partial responses were in patients with low PD-L1 expression and showed concomitant increases in cytokines associated with T-cell activation and tumor microenvironment remodeling not seen with other checkpoint therapies. We believe the novel mechanism of action of MT-6402 may allow for durable, T-cell-mediated, monotherapy activity in patients who have progressed on checkpoint therapy," added Poma. 

Molecular Templates shares are moving on heavy trading volume Tuesday. According to data from Benzinga Pro, more than 1.47 million shares have been traded in the session, compared to the stock’s 100-day average of less than 27,000 shares.

Related News: What’s Going On With SoFi Technologies Stock?

Is MTEM A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Molecular Templates‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Molecular Templates does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 110.75%, you'll need to buy a share of Lufax Holding by the June 4. Once done, you can expect to receive a nominal payout of $2.37 on June 8.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Molecular Templates will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

MTEM Price Action: According to Benzinga Pro, Molecular Templates shares are down 4.1% at $1.90 at the time of publication Tuesday.

Image: PublicDomainPictures from Pixabay